Purpose: The prospective PCM301 trial randomized 413 men with low risk prostate cancer to partial gland ablation with vascular targeted photodynamic therapy in 207 and active surveillance in 206. Two-year outcomes were reported previously. We report 4-year rates of intervention with radical therapy and further assess efficacy with biopsy results. Materials and Methods: Prostate biopsies were mandated at 12 and 24 months. Thereafter patients were monitored for radical therapy with periodic biopsies performed according to the standard of care at each institution. Ablation efficacy was assessed by biopsy results overall and in field in the treated lobe or the lobe with index cancer. Results: Conversion to radical therapy was less likely in the ablation cohort than in the surveillance cohort, including 7% vs 32% at 2 years, 15% vs 44% at 3 years and 24% vs 53% at 4 years (HR 0.31, 95% CI 0.21e0.46). Radical therapy triggers were similar in the 2 arms. Cancer progression rates overall and by grade were significantly lower in the ablation cohort (HR 0.42, 95% CI 0.29e0.59). End of study biopsy results were negative throughout the prostate in 50% of patients after ablation vs 14% after surveillance (risk difference 36%, 95% CI 28e44). Gleason 7 or higher cancer was less likely for ablation than for surveillance (16% vs 41%). Of the in field biopsies 10% contained Gleason 7 cancer after ablation vs 34% after surveillance. Conclusions: In this randomized trial of partial ablation of low risk prostate cancer photodynamic therapy significantly reduced the subsequent finding of higher grade cancer on biopsy. Consequently fewer cases were converted to radical therapy, a clinically meaningful benefit that lowered treatment related morbidity.
Key Words: prostatic neoplasms, watchful waiting, phototherapy, risk, neoplasm grading GIVEN the low probability of mortality from low risk PCa, therapeutic decisions reflect a balance between cancer control and quality of life. Current guidelines recommend AS as the preferred treatment option. 1, 2 However, in practice treatment algorithms are complex and influenced by the substantial rates of reclassification or progression to higher grade or larger volume cancer with time and by patient choice.
Low risk PCa does not always remain indolent. In published cohorts of men on AS about 25% to 60% convert to RT (eg RP or radiation therapy) within 5 to 10 years, exposing them to substantial treatment related morbidity. 3e8 Thus, there remains an unmet need for more effective control of low risk cancer with treatments that pose minimal risks to urinary, sexual or bowel function. PGA with VTP is one such therapeutic approach.
The first multicenter, phase 3, prospective randomized trial evaluating PGA as treatment for localized PCa, CLIN1001 PCM301, was recently published. 9 VTP uses TOOKADÒ (padeliporfin dipotassium), a stable, bacteriochlorophyll derived photosensitizer. 10 When excited by near infrared light (753 nm), TOOKAD generates superoxide and hydroxyl radicals which initiate a cascade of events leading to rapid vascular occlusion and subsequent coagulative necrosis of the targeted prostate tissue. 11 VTP is performed using anesthesia in an outpatient operating room. Intravenously injected TOOKAD is excited in the prostate by laser light delivered via transperineally placed light diffusers, targeting the lobe containing the largest cancer volume (hemigland ablation).
In PCM301 413 men with low risk PCa were randomized to VTP or AS. Patients with low risk PCa (Gleason score 6 or less, GG 12 1), clinical stage T2a or less and PSA 10 ng/ml or less who had 2 or 3 positive cores with MCCL 5 mm or less, or 1 positive core with MCCL between 3 and 5 mm, and prostate volume 25 to 70 cc were eligible for study inclusion. The treatment arm was not blinded to participants and investigators but primary efficacy outcomes were assessed while blinded to treatment. 9 At 12 and 24 months 12-core systematic biopsies were mandated after randomization with 6 evenly spaced cores taken from each lobe. Demographics, patient characteristics and exclusion criteria are detailed in the original report.
9
PCM301 met its co-primary and secondary end points. At 2 years in the intent to treat analysis the VTP cohort was less likely to have cancer in the biopsy at end of study (p <0.001) or progression in cancer grade or volume (p <0.001). Consequently the rate of conversion to RT at 2 years was lower in the VTP arm (p <0.001). These positive trial results led the EMA (European Medicines Agency) to approve VTP as treatment of unilateral low risk but not very low risk localized cancer in 2017.
In PCM301 the principal benefit of PGA with VTP appeared to be a substantial delay in RT compared to AS with a consequent reduction in treatment related morbidity. Since biopsy results, which were the primary end points of PCM301, were assessed and reported at 24 months, few patients converted to RT after that time were captured in the initial report. 9 Thus, we assessed the durability of PGA in the intermediate term by analyzing the rate of conversion to RT up to 4 years after randomization and by performing additional, post hoc analyses of biopsy outcomes as indicators of treatment efficacy.
MATERIALS AND METHODS
The initial PCM301 protocol (ClinicalTrials.gov NCT01310894) and extended followup with data collection up to 8 years after randomization (protocol addendum PCM301 5FU) were approved by the institutional review board centrally and at participating institutions at study initiation. All patients provided written informed consent.
To assess the intermediate results of the planned extended followup the data set was frozen on August 30, 2017. After 24 months study participants initially randomized to VTP or AS were treated by their physicians according to a local standard of care principle with management decisions, including the need for biopsy, made at the discretion of individual physicians and patients at each center. Comprehensive data, including PSA levels, biopsy results, adverse events, additional treatments and patient reported quality of life, were mandated at least annually using the approved clinical research forms submitted by the investigators.
Overall 266 patients (64%) were followed 4 or more years, including 147 (71%) in the VTP arm and 119 (58%) in the AS arm. Results at 4 years were calculated for the cumulative risk of conversion to RT and for metastasisfree, cancer specific and overall survival rates. Biopsy results were available to analyze indications for RT in 118 of the 123 patients (96%) with conversion to RT within 48 months. The types of RT included RP in 80% of cases, radiation therapy in 14% and whole gland cryotherapy or high intensity focused ultrasound in 5%. It was unknown in 1% of cases.
Additionally, post hoc analyses of annual biopsy results during the first 24 months were done to assess rates of grade progression to GG greater than 1, the location and grade of positive biopsy results in field (in the VTP treated lobe or for AS in the lobe containing the largest index cancer) and out of field (in the contralateral lobe in each cohort), and by spatial location (prostate apex, mid gland or base).
Statistical analyses were done with SASÒ, version 9.3. All randomized participants were included in efficacy analyses according to the assigned treatment. Time to progression was compared between the 2 treatment groups by the log rank test and quantified by a Cox proportional hazards regression model to derive HRs. Treatment group, patient age, number of positive cores, prostate volume and disease status at baseline served as covariates. End of study biopsy results were analyzed at 24 months. In patients who did not have a 24-month biopsy available the 12-month biopsy was considered end of study.
The chi-square test and RRs were used to compare proportions of participants in the 2 treatment groups according to the biopsy outcome. Time to initiation of RT was estimated by the Kaplan-Meier method. The 2 treatment groups were compared by the log rank test and quantified with a univariable Cox proportional hazards regression model to derive HRs at 4 years. Sensitivity analyses were done by first censoring at the time of RT in men in the 2 arms who converted by choice without evidence of progression and second by also censoring those who converted after progression by PSA or volume criteria without grade progression.
RESULTS
The lower rate of conversion to RT after VTP vs AS at 2 years (7% vs 32%) was maintained at 3 years (15% vs 44%) and at 4 years (24% vs 53%) (HR 0.31, 95% CI 0.21e0.46, p <0.001, table 1 and fig. 1 ). Triggers for conversion to RT were similar in the VTP and AS arms, including a grade increase to GG 2 or higher (61% of 36 conversions in the VTP cohort vs 49% of 87 in the AS cohort), an increase in cancer volume without a grade change (11% vs 26%), PSA failure (0% vs 2%) and patient choice (28% vs 24%) (table 2). Sensitivity analyses confirmed the substantially lower rate of conversion to RT in the VTP cohort when comparing only patients with objective evidence of progression (HR 0.29, 95% CI 0.18e0.45, p <0.001) and those with progression in grade (HR 0.38, 95% CI 0.23e0.64, p <0.001, supplementary figure, http://jurology.com/).
The proportion of study participants in each arm who converted to RT by choice without objective evidence of progression was somewhat higher in the AS arm, including 10 of 206 men (5%) in the VTP cohort vs 19 of 207 (14%) in the AS cohort (RR 0.53, 95% CI 0.25e1.11, p ¼ 0.09). Rates of 4-year metastasis-free (99% vs 99%), cancer specific (100% vs 100%) and overall survival (98% vs 99%) were similar in the 2 cohorts.
Progression rates by any of the predefined criteria and of progression in grade were separately analyzed post hoc for the whole gland and for the in field lobe (figs. 2 and 3). They are reported at 2 years since annual biopsies were not mandated in all participants beyond that point. Progression rates were significantly lower in the VTP cohort than in the AS cohort for overall progression (HR 0.35, 95% CI 0.25e0.48, p ¼ 0.001) and grade progression (HR 0.42, 95% CI 0.29e0.59, p ¼ 0.001). Reductions were even more pronounced when focusing on biopsy results in the in field lobe for overall progression (HR 0.21, 95% CI 0.14e0.31, p <0.001) and for grade progression (HR 0.25, 95% CI 0.16e0.40, p <0.001). Figure 1 . Kaplan-Meier estimated probability of conversion to radical therapy with time in each arm. End of study biopsies were negative throughout the prostate in 50% of the VTP cohort vs 14% of the AS cohort (risk difference 36%, 95% CI 28e44, p <0.001, table 3). Higher grade cancer (GG greater than 1) was less likely on biopsy after VTP than after AS (16% vs 41%, risk difference e25%, 95% CI e33ee16, p <0.001). When comparing in field biopsy results in the VTP and AS cohorts, cancer was found after VTP in 25% vs 65% in the AS cohort while high grade cancer (GG greater than 1) was noted in 10% after VTP vs in 34% in the AS cohort.
There was no significant difference between the 2 arms in the rate of positive out of field biopsies overall or the rate of GG greater than 1 (table 3) .
Spatially biopsy results were analyzed in 85 consecutive patients in the VTP arm with data available. Prior to treatment 39 (46%), 40 (47%) and 43 patients (51%) had positive biopsy results in the apex, mid gland and base, respectively. Location data were missing on 15 patients (18%). There was no significant difference in the negative biopsy rate at 1 year by location in the VTP treated lobe, 
DISCUSSION
With the safety and efficacy of hemigland ablation with VTP established in phase 1-2 trials 13e16 PCM301 was designed to compare VTP outcomes against the outcomes of AS, which is the standard of care for men with low risk cancer. 9 Of particular interest was the ability of VTP to eliminate biopsy detectable cancer in the prostate and prevent progression or reclassification in cancer grade and extent, which typically leads patients to refuse AS initially or convert to RT subsequently. 17 In the initial report of the results of PCM301 VTP substantially reduced progression overall and by each predefined criterion compared to AS at 24 months. 9 In that time frame conversions to RT in either arm were driven largely by the new finding of GG 2 or higher on biopsy and they were substantially lower in the VTP cohort than in the AS group. Morbidity was low, and sexual, urinary and bowel functions were preserved at 24 months despite subsequent contralateral VTP treatment in 32%, ipsilateral retreatment in 11%, and contralateral treatment and retreatment in 2% of the VTP cohort.
While conversion to RT was a secondary end point of PCM301, the impact of VTP on the conversion rate at 24 months was impressive at 7% vs 32% in the AS arm. Avoidance of RT and the resulting effects on function and quality of life appeared to be a major clinical benefit of VTP in men with low risk, intermediate volume PCa. Consequently when analyzing longer term outcomes, we were particularly interested in the durability of this apparent benefit and the degree to which conversions were based on objective indicators of disease progression rather than on patient and physician choice alone.
In fact, the reduced rate of conversion to RT at 2 years was maintained through 4 years (table 1 and fig. 1 ). It was largely the result of the lower rate of progression to higher grade cancer in the VTP cohort (table 2) . Compared with AS, VTP significantly reduced overall biopsy progression to GG 2 or higher with an even stronger reduction in the in field lobe (figs. 2 and 3). End of study biopsies at 24 months identified GG 2 or higher cancer in only 16% of the VTP cohort compared with 41% of the AS group (table 3) . In field progression to GG 2 or higher was identified in only 10% of men after VTP compared to 34% on AS, supporting the ablative efficacy of VTP without increasing progression in untreated, out of field areas (table 3) . Finally, conversion to negative biopsy results after VTP was equally likely throughout the prostate apex, mid gland and base.
There are important implications of this study. In men on AS for low risk prostate cancer progression to or the finding of GG 2 or higher on biopsy commonly triggers definitive treatment with RP or radiation therapy since such grade progression is associated with higher rates of metastasis and death from cancer. 3 Converting to RT risks adverse effects on sexual, urinary and bowel function. 1 In men on AS progression to GG 2 or higher is strongly associated with conversion to RT, making GG 2 or higher a useful predictive biomarker of cancer progression and subsequent treatment related morbidity. 3, 6, 7, 12 Nevertheless, there remain concerns about PGA of low risk prostate cancer using any technology. One issue is whether current biopsy and imaging techniques can sufficiently localize the index cancer even when the therapeutic target is an entire lobe. In the current study VTP was not completely effective in eliminating cancer in the targeted lobe. Cancer was present on biopsy in 25% of patients after VTP, although only 10% had GG 2 or higher cancer in the treated lobe (table 3) .
There are other limitations to this study. Cancers were not characterized at diagnosis as thoroughly as might be done in a clinical trial of PGA today. Neither saturation nor confirmatory biopsies, nor multiparametric MRI was performed to further characterize the cancer found on the initial diagnostic biopsy. These factors may help explain the observed 53% rate of conversion to RT in the AS arm at 4 years. Although it is higher than in some contemporary series, this rate of RT is not inconsistent with other large AS studies, which show a RT rate of 25% to 60% within 5 to 10 years.
3e6,18
Other explanations include the exclusion of very low risk cancers from PCM301, the high compliance rate with protocol mandated annual biopsies and the stringent biopsy criteria used to trigger the recommendation for RT (eg the number of positive cores and MCCL do not serve as RT triggers in most AS studies). Nevertheless, the 12-core systematic techniques applied for the initial diagnostic biopsy and for subsequent monitoring biopsies are in accord with the standard of care in North America today. With the randomization of patients at baseline these factors affected the 2 arms similarly, magnifying the importance of the differences observed for VTP treatment.
Other limitations include the lack of protocol mandated biopsies after 24 months, which limited documentation of the objective progression rate in each arm beyond 2 years. However, we have biopsy results to document the reason for conversion in 96% of the 123 patients who underwent RT. Patient reported functional outcomes (erectile dysfunction, urinary and bowel symptoms) are not yet uniformly available beyond 24 months from the initial randomization. Progression to clinical stage T3 cancer was more common in the AS cohort but there were too few events to assess the long-term effectiveness of hemiablation with VTP in reducing clinical cancer events. More data will become available with further followup of the PCM301 trial and the post-marketing studies under way in Europe.
To our knowledge the current study provides the longest reported level 1 evidence of the safety and efficacy of PGA of PCa published to date. Based on data from multiple phase 1 to 3 clinical trials, including PCM301, PGA using a strategy targeting 1 full lobe (hemigland ablation) with VTP, followed by ipsilateral retreatment of persistent cancer and contralateral ablation if significant cancer was found on subsequent biopsy, is safe with few adverse effects on quality of life. 9,13e16 Furthermore, this strategy substantially reduces the likelihood of progression to higher Gleason grade and/or larger volume cancer on subsequent biopsy, markedly decreasing the rate of intervention with RT with its attendant morbidity. 9 Thus, PGA with VTP provides a clinically meaningful benefit in select men with low risk but not very low risk prostate cancer.
CONCLUSIONS
To our knowledge PCM301 is the only prospective, multi-institutional, randomized trial comparing PGA and AS of low risk prostate cancer. At 4 years of followup PGA with VTP decreased the risk of overall and grade progression, and consequently reduced the rate of conversion to RT. This is a clinically meaningful outcome which lowers treatment related morbidity compared with AS while improving cancer control.
These authors completed the first randomized, controlled trial demonstrating a benefit to partial prostate ablation in early stage prostate cancer, now with 4 years of followup. While we have traditionally looked for a benefit in cancer specific or overall survival before concluding that a cancer treatment is effective, this is hard to demonstrate even for prostatectomy for this disease. Thus, a reduction in the burden of care (ie radical whole gland prostate therapy) would also be beneficial as it reduces the cost and side effects of treatment.
This trial clearly has some issues with loose entry criteria and poorly defined parameters around the treatment extent. Nevertheless, it shows a meaningful reduction in the treatment burden at least at 4 years after trial entry. However, I would suggest that perhaps they are a bit off target in the study population. Since we know that approximately 50% of patients at low risk do not progress in 10 years (and perhaps that number is even larger with the current treatment paradigm using fusion biopsies), probably the majority of the men in the treatment arm received no benefit from treatment. An alternative approach would be to identify men with focal prostate cancer but in whom strict surveillance criteria failed because of grade or grade progression on surveillance. These men could be treated with a treatment modality such as TOOKAD and see how long they can be maintained on surveillance. In this approach all men would have at least the potential to derive some benefit from the treatment.
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REPLY BY AUTHORS
We appreciate the comments acknowledging the PCM301 trial as the first published randomized study comparing PGA to active surveillance. We also agree that in carefully selected patients PGA reduces the aggregate treatment burden. This becomes a meaningful clinical benefit and an appropriate end point for clinical trials. After all, the benefit of AS itself is avoidance of the morbidity and the adverse impact on quality of life with RT. If PGA can further reduce the need for RT, it would provide a valuable supplement to active surveillance alone.
As an end point for clinical trials of innovative therapeutics for early stage prostate (and many other) cancers, avoiding RT is useful well in advance of the traditional survival outcomes such as overall or cancer specific survival. They would require impractically long trials with the end points obscured by the many additional life prolonging treatments that such patients would receive with time.
As more studies accumulate to confirm the safety and efficacy of PGA, the challenge will be proper patient selection, as the comments point out. PCM301 was designed nearly 10 years ago when the standard of care was systematic 12-core transrectal ultrasound guided biopsies for diagnosis, when MRI was not yet widely accepted, and when revisions of the Gleason grading system, which reclassifies many low grade tumors as intermediate grade, had not been widely adopted in practice. Today with better characterization of cancers by multiparametric MRI, MRI targeted fusion and confirmatory biopsies along with novel biomarkers in blood and tissue one would generally recommend AS in most men with confirmed low risk cancer.
A trial of PGA today might more appropriately include select high volume Gleason 6 (GG1) cancers, low volume, favorable Gleason 3 + 4 (GG2) cancers, especially those visible by MRI, and some intermediate volume GG1 cancers in otherwise healthy men with long life expectancy (eg more than 20 years).
Reducing the burden of treatment should be a priority for these cancers, whether at initial diagnosis or after progression on active surveillance. Radical surgery or radiation therapy alone or in combination with systemic therapy will continue to serve well those with more aggressive and/or widespread cancer.
